Management of Advanced Non-Small Cell Lung Cancer (NSCLC) and Clinical Outcomes in Patients Who Received Gefitinib in Thailand

AstraZeneca

Status: Completed

Conditions: Lung Cancer

Study type: Observational

Funder types: Industry

Identifiers

NCT01130961

NIS-OTH-IRE-2009/1

Details and patient eligibility

About

The purpose of this study is to determine progression-free survival of lung cancer patients who received gefitinib in clinical practice in Thailand.

Enrollment: 104 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosed as having lung cancer based on histological/cytological findings
• Admitted to the hospital between January 2004 and December 2008
• Treated with gefitinib for at least 3 months

Exclusion criteria

• Involvement in the planning and/or conduct of the study
• Participation in another clinical study during the last 3 months